Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2023-03-13
Target enrollment:
Participant gender:
Summary
This study is testing the safety and tolerability of subcutaneous semaglutide in participants
with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous
injection of semaglutide in doses decided by the study doctor's criteria, according to
participant's personal needs. The study will last for about 24 weeks. Participants will have
4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study
(blood and urine samples).